Measurement of complexed PSA in the differential diagnosis between prostate cancer and benign prostate hyperplasia

Prostate

Volumn 42, Issue 3, 2000, Pages 181-185

  Filella, Xavier ^a   Alcover, Juan ^a   Molina, Rafael ^a   Corral, Juan Manuel ^a   Carretero, Pablo ^a   Ballesta, Antonio Manuel ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Complexed PSA; Prostate cancer; Total PSA

Indexed keywords

COMPLEXED PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; ARTICLE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; ENZYME IMMUNOASSAY; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY;

DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERPLASIA; MALE; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0034651587     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(20000215)42:3<181::AID-PROS3>3.0.CO;2-M     Document Type: Article

References (20)

1. Ambruster DA. Prostate-specific antigen: biochemistry, analytical methods, and clinical application. Clin Chem 1993;39:181-195.
2. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, Cooner WH. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992;147:815-816.
3. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-2220.
4. Oesterling JE. Age-specific ranges for serum PSA. N Engl J Med 1996;335:345-346.
5. Abrahamsson PA, Lilja H, Oesterling JE. Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen. Urol Clin North Am 1997;24:353-365.
6. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998; 159:5-12.
7. Allard WJ, Zhou Z, Yeung KK. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem 1998;44:1216-1223.
8. Brawer MK, Meyer GE, Letran JL, Bankson DD, Morris DL, Yeung KK, Allard WJ. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998;52:372-378.
9. Reissigl A, Klocker H, Pointner J, Ennemoser O, Falk M, Bartsch G. Improvement of prostate cancer screening by determination of the ratio free/total PSA in addition to PSA levels. Prostate 1997;30:243-247.
10. Bangma CH, Rietbergen JB, Kranse R, Blijenberg BG, Petterson K, Schröder FH. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol 1997;157: 2191-2196.
11. Filella X, Alcover J, Molina R, Rodríguez A, Carretero P, Ballesta AM. Clinical evaluation of free PSA/total PSA ratio in the diagnosis of prostate cancer. Eur J Cancer 1997;33:1226-1229.
12. Catalona WJ, Partin AW, Slawin KM, Bra wer MK, Flanigan RC, Patel A, Richie JP, de Kernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA 1998;279:1542-1547.
13. Abrahamsson PA, Lilja H. Free and complexed forms of prostate-specific antigen in serum. Tumour Marker Update 1994;6: 1-4.
14. Jung K, Brux B, Knäbich A, Lein M, Sinha P, Schnorr D, Loening SA. A gap between total Prostate-specific antigen and the sum of free prostate-specific antigen plus α1-antichymotrypsin-prostate-specific antigen in patients with prostate carcinoma but not in those with benign prostate hyperplasia. Clin Chem 1999; 45:422-424.
15. Yemoto CE, Stamey T. Observations on complexed PSA (cPSA) in separating biopsy-negative from biopsy-positive men in a university setting. J Urol 1999;161:208.
16. Filella X, Alcover J, Molina R, Carrere W, Carretero P, Ballesta AM. Usefulness of Prostate-specific antigen density as a diagnostic test of prostate cancer. Tumour Biol 1996;17:20-26.
17. Filella X, Molina R, Ballesta AM, Gil MJ, Allepuz C, Rioja LA. Value of PSA (prostate-specific antigen) in the detection of prostate cancer in patients with urological symptoms. Results of a multicentre study. Eur J Cancer 1996;32:1125-1128.
18. Piironen T, Pettersson K, Suonpaa M, Stenman UH, Oesterling JE, Lovgren T, Lilja H. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. Urology [Suppl] 1996;48:81-87.
19. España F, Martinez M, Royo M, Vera CD, Estelles A, Aznar J, Jimenez-Cruz JF. Reference ranges for the concentrations of total and complexed plasma prostate-specific antigen and their ratios in patients with benign prostate hyperplasia. Eur Urol 1997;32: 268-272.
20. Woodrum D, French C, Shamel LB. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and storage conditions. Urology [Suppl] 1996;48: 33-39.